Rapid Autopsy Protocol for Patients With Small Cell Lung Cancer
Rapid ("Warm") Autopsy Protocol for Patients With Small Cell Lung Cancer
1 other identifier
observational
30
1 country
3
Brief Summary
This is pilot study to establish a rapid autopsy program in Small Cell Lung Cancer (SCLC) at the Indiana University Simon Comprehensive Cancer Center and outline the components necessary for tumor tissue collection.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Aug 2022
Longer than P75 for all trials
3 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 31, 2022
CompletedFirst Submitted
Initial submission to the registry
May 22, 2023
CompletedFirst Posted
Study publicly available on registry
June 5, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2030
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 31, 2031
July 20, 2025
July 1, 2025
8.3 years
May 22, 2023
July 16, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Determining the Feasibility of the Creation of a Rapid Autopsy Program at IUSCCC for SCLC through enrollment and sample collections
5 years
Utilization of Tissue to Better Understand the Complex Biology of SCLC
Utilize tissue obtained from rapid autopsies to generate novel patient derived xenograft models and tumor cell lines, in addition to RNA, whole exome and whole genome sequencing, protein extraction to better understand the complex biology of SCLC and set up an infrastructure to develop relevant clinical models that will allow the development of better therapies.
5 years
Study Arms (1)
Active SCLC Diagnosis
Interventions
Lung, liver, skin, subcutaneous metastases, and blood specimens may be collected via rapid autopsy within 10 hours of expiration.
Eligibility Criteria
Any patient with active SCLC being seen at IUSCCC clinics.
You may qualify if:
- ≥ 18 years old at the time of informed consent
- Written informed consent and HIPAA authorization for release of personal health information.
- Active SCLC diagnosis.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (3)
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Indianapolis, Indiana, 46202, United States
Roudebush VA Medical Center
Indianapolis, Indiana, 46202, United States
Sidney and Lois Eskenazi Hospital
Indianapolis, Indiana, 46202, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Shadia I. Jalal, MD
Indiana University
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate Professor in the Department of Medicine at Indiana University
Study Record Dates
First Submitted
May 22, 2023
First Posted
June 5, 2023
Study Start
August 31, 2022
Primary Completion (Estimated)
December 31, 2030
Study Completion (Estimated)
December 31, 2031
Last Updated
July 20, 2025
Record last verified: 2025-07